摘要
目的探讨替诺福韦酯联合拉米夫定治疗艾滋病合并乙型肝炎病毒感染的临床疗效。方法选取攀枝花市第四人民医院2015年3月—2016年3月收治的艾滋病合并乙型肝炎病毒感染患者100例,随机分为对照组和观察组,每组50例。对照组患者给予拉米夫定单一用药治疗,观察组患者在对照组基础上给予替诺福韦酯治疗,两组患者均持续治疗8周。观察比较两组患者治疗24、48周丙氨酸氨基转移酶(ALT)复常率及HBV-DNA血清载量。结果治疗24、48周后,观察组患者ALT复常率高于对照组(P<0.05)。治疗前,两组患者HBV-DNA血清载量比较,差异无统计学意义(P>0.05);治疗后24、48周后,观察组患者HBV-DNA血清载量低于对照组(P<0.05)。结论替诺福韦酯联合拉米夫定治疗艾滋病合并乙型肝炎病毒感染的临床疗效较佳,可明显提高ALT复常率,降低HBV-DNA血清载量。
Objective To explore the clinical efficacy of tenofovir disoproxil combined with lamivudine in treating HIV with hepatitis B virus. Methods A total of 100 cases of HIV with hepatitis B virus infected patients were selected from March 2015 to March 2016 in the Fourth People＇s Hospital of Panzhihua City, which were randomly divided into control group and observation group, 50 cases in each group. Control group was given lamivudine, observation group was given tenofovir disoproxil based on control group. The ALT normalization rate and the serum HBV - DNA load after treatment of 24, 48 weeks were observed and compared between the two groups. Results After treatment of 24, 48 weeks, the ALT normalization rate of observation group were significantly higher than control group （ P 〈 0.05 ）. Before treatment, no statistically significant difference of serum HBV - DNA load was found between the two groups （ P 〉 0. 05 ） ; after treatment of 24, 48 weeks, the serum HBV - DNA load of observation group were lower than control group （ P 〈 0. 05 ）. Conclusion Tenofovir disoproxil combined with lamivudine have a significantly clinical effect, it can obviously increase the ALT normalization rate and reduce serum HBV - DNA load.
出处
《临床合理用药杂志》
2017年第6期21-22,共2页
Chinese Journal of Clinical Rational Drug Use
